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Mice overexpressing the longevity protein SIRT6
or deficient for the liver’s most prevalent microRNA
miR-122 display a similar set of phenotypes,
including improved lipid profile and protection
against damage linked to obesity. Here, we show
that miR-122 and SIRT6 negatively regulate each
other’s expression. SIRT6 downregulates miR-122
by deacetylating H3K56 in the promoter region.
MiR-122 binds to three sites on the SIRT6 30 UTR
and reduces its levels. The interplay between SIRT6
and miR-122 is manifested in two physiologically
relevant ways in the liver. First, they oppositely
regulate a similar set of metabolic genes and fatty
acid b-oxidation. Second, in hepatocellular carci-
noma patients, loss of a negative correlation be-
tween SIRT6 and miR-122 expression is significantly
associated with better prognosis. These findings
show that SIRT6 and miR-122 negatively regulate
each other to control various aspects of liver physi-
ology and SIRT6-miR-122 correlation may serve as
a biomarker for hepatocarcinoma prognosis.
INTRODUCTION
Sirtuins are homologs of the yeast NAD+-dependent SIR2 de-
acetylase that have been shown to regulate the lifespan of yeast,
worms, and flies (Kaeberlein et al., 1999; Rogina and Helfand,
2004; Tissenbaum and Guarente, 2001). Of the seven mamma-
lian sirtuins, SIRT1–SIRT7, SIRT6 was shown to directly regulate
mammalian lifespan (Kanfi et al., 2012) and to play amajor role in
regulating the response to nutrient levels (Kanfi et al., 2008,
2010). SIRT6-deficient mice display a set of premature-aging-
like phenotypes and live up to 4 weeks (Mostoslavsky et al.,
2006). SIRT6/ mice exhibit hypoglycemia as a result of a sig-
nificant increase in glucose uptake due to higher expression
levels of the glucose transporter, GLUT1. Similarly, liver-specific
SIRT6 knockout mice exhibit increased glycolysis, fatty liver, tri-
glyceride synthesis, and reduced b-oxidation (Kim et al., 2010).
Conversely, transgenic mice overexpressing SIRT6 (MOSES234 Cell Reports 14, 234–242, January 12, 2016 ª2016 The Authorsmice) live significantly longer than their wild-type (WT) littermates
(Kanfi et al., 2012). When fed a high-fat diet, MOSES mice accu-
mulate significantly less visceral fat, low-density lipoprotein
(LDL) cholesterol, and triglycerides when compared to their WT
littermates. The mechanism underlying the regulation of choles-
terol and triglyceride homeostasis by SIRT6 is, at least in part,
repression of the sterol regulatory element binding proteins
(SREBP1 and SREBP2), important lipogenic transcription fac-
tors (Elhanati et al., 2013).
MicroRNAs (miRNAs) are a class of endogenously expressed
small regulatory noncoding RNAs that are thought to negatively
regulate target mRNAs by binding with imperfect complemen-
tarity to their 30 untranslated region (30 UTR) (Ambros, 2004;
Bartel, 2004). Hundreds of different miRNAs are encoded in
individual genomes, and approximately 30% of all human genes
are predicted to be subject to miRNA regulation. However, with
regard to hepatic SIRT6, to date, only miR-33a/miR-33b has
been shown to regulate SIRT6 levels (Da´valos et al., 2011; Elha-
nati et al., 2013). MicroRNA-122 (miR-122), which is encoded
within the second exon of the long noncoding RNA (lincRNA)
hcr, was one of the first examples of a tissue-specific miRNA
and is highly expressed in the liver, where it constitutes 70% of
the total mirnome (Bhattacharyya et al., 2006; Chang et al.,
2004; Jopling, 2012; Li et al., 2011). Interestingly, SIRT6 and
miR-122 participate inmany similar pathways but act in opposite
directions. MiR-122 was found to have an important role in liver
function, as studies on this miRNA showed that miR-122 is
involved in multiple metabolic processes, including cholesterol
biosynthesis (Kr€utzfeldt et al., 2005), fatty acid synthesis, and
b-oxidation (Esau et al., 2006). Mice lacking miR-122 have
reduced plasma cholesterol levels, increased hepatic fatty acid
oxidation, and decreased hepatic fatty acid and cholesterol syn-
thesis rates. The result was also observed in a mouse model of
diet-induced obesity (Esau et al., 2006). Like SIRT6 overexpres-
sion, miR-122 was also found to regulate SREBP1 and SREBP2,
as inhibition of miR-122 results in a reduction of SREBP1 and
SREBP2 levels (Menon et al., 2013). Regarding cancer, similar
to SIRT6, miR-122 was also suggested to function as a tumor
suppressor. MiR-122-deficient or liver-specific-deficient mice
exhibit an increase in age-dependent hepatocellular carcinoma
(HCC) (Hsu et al., 2012; Tsai et al., 2012). In humans, repression
of miR-122 was reported in a subset of primary tumors charac-
terized by poor prognosis, and miR-122 was shown to affect
Figure 1. Mir-122 Negatively Regulates
SIRT6
(A) Schematic representation of the three putative
biding sites (BS1–BS3) on SIRT6 30 UTR for miR-
122. The sequence of miR-122 and the sites and
positions of BS1-3 on SIRT6 30 UTR are indicated;
the seed sequence is underlined.
(B) Activity of luciferase reporter constructs fused
to the 30 UTR of human SIRT6, in Huh7 cells
transfected with control plasmid (vehicle), miR-
122, or miR-122 with double or triple mutations.
**p < 0.01.
(C) Representative western blot (out of three)
showing that overexpression of miR-122 re-
presses SIRT6.
(D) Representative western blot (out of three)
showing that overexpression of antagomir against
miR-122 increases SIRT6 expression. a-tubulin
and b-actin were used as loading controls.
R.I., relative intensity as calculated by ImageJ
software.the viability and apoptosis of HCC cells (Coulouarn et al., 2009;
Wu et al., 2009). Surprisingly, despite the significant amount of
data on miR-122-dependent phenotypes, our knowledge of its
regulation at the molecular level is severely limited.
Here, we demonstrate reciprocal regulation between miR-122
and SIRT6 expression. MiR-122 binds to SIRT6 30 UTR and
represses its levels, whereas SIRT6 downregulates miR-122 by
deacetylating H3K56 on its promoter region. Overexpressing
SIRT6 in mouse liver and in tissue culture blocks miR-122
repression of various hepatic genes and inhibits the regulation
of miR-122 on fatty acid oxidation. Moreover, the degree of cor-
relation between the expression levels of SIRT6 and miR-122
can be used as a biomarker for the effectiveness of treatment
and survival of HCC patients. Thus, we describe a regulatory
cascade of SIRT6 and miR-122 in regulating liver activities.
RESULTS
Mir-122 Negatively Regulates SIRT6
SIRT6 overexpression and liver-specific knockouts of miR-122
share many similar phenotypes. Thus, we examined whether
SIRT6 and miR-122 reciprocally regulate each other. Compari-
son of miR-122’s seed sequence to the SIRT6 mRNA sequence
demonstrated that miR-122 could potentially bind to the SIRT6
30 UTR (Figure 1A). We therefore suggested that SIRT6 might
be subject to miR-122 regulation. To examine this possibility,
human hepatocarcinoma Huh7 cells were transfected with
luciferase expression plasmid in which the SIRT6 30 UTR was
integrated downstream of the firefly luciferase gene. ThisCell Reports 14, 234–242plasmid was co-transfected with empty
vector control (vehicle), miR-122 expres-
sion plasmid, or miR-122 expression
plasmid carrying double or triple muta-
tions in the seed sequence of miR-122.
As shown in Figure 1B, miR-122 expres-
sion, but not control plasmid, significantly
repressed SIRT6’s 30 UTR-Luciferase
expression. Moreover, double or triple mutations in the seed
sequence of miR-122 blocked the repression of luciferase
expression (Figure 1B). These findings suggest that miR-122
regulates SIRT6 expression.
To further explore this observation, SIRT6 expression levels
were examined in Huh7 cells transfected with miR-122 express-
ing vector or with control vehicle. MiR-122 overexpression
resulted in a significant 10% reduction in SIRT6 mRNA levels
(Figure S1) and a significant 60% average reduction (p = 0.002)
in SIRT6 protein levels (Figure 1C). Conversely, overexpression
of antagomir against miR-122, but not of scrambled control
RNA (SC), resulted in a significant 80% average increase (p =
0.04) in SIRT6 protein levels (Figure 1D). Altogether, these find-
ings demonstrate that SIRT6 is a target for miR-122 regulation.
Differential Affinity of miR-122 Binding on SIRT6’s
30 UTR
To experimentally measure affinity of miR-122 and SIRT6 asso-
ciation, surface plasmon resonance (SPR) assay was used to
examine the binding parameters of miR-122 with several puta-
tive binding sites on SIRT6 30 UTR (miR-122-BS1 to BS3) and
the full length SIRT6 30 UTR (510 bp) (Figures 2A–2D). SPR was
used recently to determine binding affinities between miR and
their corresponding targets (Hanin et al., 2014). For assay valida-
tion, CAT1, a known target of miR-122 (Bhattacharyya et al.,
2006), was used as a positive control, and the binding site of
miR-33 on SIRT6 30 UTRwas used as a negative control. In addi-
tion, the affinities of miR-122 andmiR-766 to their corresponding
binding sites were compared (Figure 2E)., January 12, 2016 ª2016 The Authors 235
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Figure 2. Quantified miR-122-Target Inter-
actions
(A–D) SPR sensograms representing binding of
30 UTR putative binding site fragments (A–C) and
30 UTR (D) to SPR chip with streptavidin-immobilized
biotinylatedmiR-122 oligo. Analytes were injected at
a series of increasing concentrations of 0.78, 1.56,
3.125, 6.25, 12.5, 25, 50, and 100 mg/mL. N.B., no
binding.
(E) Kinetic association and dissociation constants
(kon and koff) as well as SPR-measured affinity con-
stants (KD) for interactions of miR-122 and various
analytes.
(F) Activity of luciferase reporter constructs fused
to the 30 UTR of human SIRT6 or 30 UTR carrying
mutations in BS1 (Mut. 1), BS2 (Mut. 2), BS3 (Mut. 3),
or the various combinations of mutations in Huh7
cells transfected with miR-122. Scrambled miR was
used as control. *p < 0.05; **p < 0.01; ***p < 0.001.Affinity of full-length SIRT6 30 UTR for miR-122 was the highest
(22 nM; Figure 2D) as compared to affinity of individual binding
sites, whose affinity constants were in the range of 3 to 5 mM.
Both faster association rate and slower dissociation rate contrib-
uted to this greater affinity. CAT1 sites also interacted with
miR-122 with binding affinities similar to those of miR-122-BS1
to BS3. Interestingly, when another RNA binding pair, a low-
abundance miR-766, previously shown to regulate SIRT6
(Sharma et al., 2013), was tested in SPR assay for interaction
with its predicted binding site, we determined a level of affinity
that was intermediate between those of miR-122 with its individ-
ual target fragment binding sites and its full-length 30 UTR target.
This may suggest some differences in the regulatory action of
those two miRNAs.
Next, we further investigated the differential regulation of
SIRT6 by miR-122 under in vivo conditions. To do so, miR-122
was transfected into Huh7 hepatocellular cells together with a
plasmid expressing the luciferase gene adjacent to one of the
following options: SIRT6 30 UTR; SIRT6 30 UTR carrying mutation
at either BS1, BS2, or BS3; or with various combinations of these
mutations: BS1/BS2, BS1/BS3, BS2/BS3 and BS1/BS2/BS3.
Scrambled miR was used as control together with a control for
SIRT6 30 UTR. As shown in Figure 2F, miR-122 reduces SIRT6
30-UTR-luciferase expression by40%, each of the single muta-
tions reduced it by25%, each of the double mutants reduced it236 Cell Reports 14, 234–242, January 12, 2016 ª2016 The Authorsby 12%, and the triple mutant had no ef-
fect on the luciferase expression. Thus, as
shown by the SPR experiment, miR-122 re-
presses SIRT6 by a differential repression
mode depending on the number of binding
sites on its 30 UTR.
SIRT6 Negatively Regulates miR-122
Next, we examined whether SIRT6 regu-
lates miR-122. Quantitative real-time
PCR showed that overexpression of
SIRT6 in Huh7 cells resulted in a 40%
decrease in miR-122 levels (Figure 3A,
left graph). Previous studies showed thatSIRT6 negatively regulates the transcription of its target genes
by binding and deacetylating histone H3 K9 and K56 on their
promoters (Michishita et al., 2008, 2009; Yang et al., 2009).
Indeed, chromatin immunoprecipitation (ChIP) followed by
quantitative real-time PCR demonstrated that SIRT6 binds to
the promoter region of MIR-122 adjacent to the transcription
start site of the miR (Figure 3B, left graph). Moreover, additional
ChIP analysis showed that in comparison to WT cells, the levels
of H3K56Ac, but not H3K9Ac, on the promoter were signifi-
cantly lower in SIRT6-overexpressing cells (Figure 3C, left
graph; Figure S2). Catalytic inactive SIRT6 (H133Y) binds to
MIR-122 promoter but has no effect on miR-122 expression
and H3K56 acetylation levels (Figures 3A–3C, left graphs).
Small interfering RNA (siRNA) against SIRT6 significantly in-
creases miR-122 expression and H3K56Ac levels and blocks
SIRT6 binding to MIR-122 promoter (Figures 3A–3C right
graphs). Thus, these results show that SIRT6 binds to MIR-
122 promoter and represses its transcription by deacetylating
histone H3K56.
To further investigate the regulation of miR-122 by SIRT6, we
examined the effect of SIRT6 overexpression on several putative
miR-122 targets. Comparison between bioinformatics analysis
of potential miR-122 target genes and SIRT6 hepatic-regulated
genes identified the genes IGFBP1, IGFBP2, and GADD45g.
As shown in Figure 3D, SIRT6F overexpression resulted in a
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Figure 3. SIRT6 Negatively Regulates
miR-122
(A–C) Relative expression of miR-122 in (A) Huh7
cells overexpressing SIRT6, catalytically inactive
SIRT6 (H133Y), or siRNA against SIRT6 and their
appropriate controls empty plasmid (vehicle) or
scrambled siRNA. A ChIP assay was followed by
quantitative real-time PCR measuring (B) SIRT6 or
H133Y binding or (C) acetylated histone H3K56
levels at the promoter region of miR-122 in these
cells. Anti-H3 was used as positive control (data
not shown).
(D and E) RNA (D) or protein (E) expression of three
putative targets of miR-122, IGFBP1, IGFBP2, and
GADD45g,measuredbyquantitative real-timePCR
in Huh7 hepatocarcinoma cells overexpressing
either SIRT6, miR-122, antagomir against miR-122
(AM122), or SIRT6 andmiR-122. All results shown in
this graphare relative toWT (=1).Experimentswere
done in biological tetra/triplicates. R.I., relative in-
tensity; *p < 0.05; **p < 0.01.significant increase in the expression levels of these genes.
Overexpression of miR-122 resulted in a significant decrease
in IGFBP2 RNA expression levels (Figure 3D). Conversely, over-
expression of antagomir against miR-122 significantly increased
IGFBP2 levels. Moreover, overexpressing miR-122 and SIRT6
together reduces the effect of SIRT6 alone on these genes and
importantly restored IGFBP2 expression toWT levels (Figure 3D).
IGFBP2 protein levels changed accordingly by these treatments
(Figure 3E). Interestingly, as shown with numerous miRs (for
example, see Bhattacharyya et al., 2006), despite the lack of
significant effect of miR-122 and its antagomir on IGFBP1 and
GADD45g RNA levels, overexpression of miR-122 still reduces
these protein levels (Figure 3E). In line with its effect on RNA
levels, overexpression of SIRT6 significantly induces IGFBP1/
IGFBP2 and GADD45g protein levels (Figure 3E). Thus, SIRT6
and miR-122 reciprocally regulate each other’s function on
shared target genes.
MiR-122 and SIRT6 Regulate Metabolic Pathways
Next, we followed additional functional interactions between
SIRT6- and miR-122-dependent pathways. MiR-122 inhibition
in normal mice resulted in increased hepatic fatty acid b-oxida-
tion, suggesting that SIRT6 might regulate b-oxidation via miR-
122. In support of this, we recently showed that SIRT6 overex-
pression leads to increased expression of HADHB, CPT1, and
CROT, rate-limiting enzymes in b-oxidation of free fatty acids
(Elhanati et al., 2013). Thus, we examined whether levels of these
genes and another b-oxidation gene, ACLY, are regulated by
miR-122 as well. As shown in Figure 4A, overexpression of
SIRT6 significantly increased their levels. MiR-122 or its antago-
mir (AM122) significantly decreases or increases, respectively,
the expression levels of HADHB, CPT1, CROT, and ACLY. Over-
expression of SIRT6 and miR-122 increases the levels of theseCell Reports 14, 234–242genes to similar levels as the antagomir
(Figure 4A). A similar effect was found
on the expression of insulin-signaling
genes IRS1 and IRS2 (Figure 4B). Wenext directly measured the b-oxidation process in hepatocytes
by measuring the oxygen consumption rate (OCR). Importantly,
Zhong et al. reported that SIRT6 deficiency results in an OCR
reduction due to Warburg shift (Zhong et al., 2010). However,
here the cells were supplemented with BSA-conjugated palmitic
acid, and therefore we directly measure b-oxidation. As shown
in Figure 4C, overexpression of antagomir against miR-122
resulted in an increase in b-oxidation, whilemiR-122 overexpres-
sion resulted in decreased activity. Similarly, overexpression of
SIRT6 resulted in an increase in b-oxidation, while knockdown
of SIRT6 by siRNA resulted in a decrease (Figure 4C). Down-
regulation of SIRT6 by siRNA together with overexpression
of antagomir against miR-122 resulted in lower b-oxidation
compared to WT cells (Figure 4C). Last, overexpression of
SIRT6 together with miR-122 blocks the effect of miR-122 alone
on b-oxidation (Figure 4C). Thus, SIRT6 and miR-122 jointly
regulate b-oxidation.
Mice overexpressing SIRT6 or deficient for miR-122 are pro-
tected against the physiological damages of obesity. Thus, first
we examined liver miR-122 levels in MOSES or WT littermate
mice fed chow diet or high-fat diet (HFD). A twofold decrease
in miR-122 expression was detected in the liver of SIRT6-over-
expressing transgenic male mice relative to WT littermates
(Figure 4D). Interestingly, the increase in miR-122 upon HFD
was blocked in MOSES mice (Figure 4D), suggesting that
repression of miR-122 might mediate some of the positive
effects of SIRT6 on HFD. Thus, we followed expression levels
of the b-oxidation-related genes Hadhb, Cpt1, Crot, and Acly
along with the insulin-signaling-related genes Irs1, Irs2, Igfbp1,
and Igfbp2. In comparison to WT mice, when fed regular
chow diet, the RNA expression levels of HADHB, CPT1,
CROT, IRS1, IGFBP1, and IGFBP2 were significantly higher in
MOSES mice (Figures 4E and 4F). Higher expression was found, January 12, 2016 ª2016 The Authors 237
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Figure 4. Opposite Regulation of Metabolic Pathways by SIRT6 and miR-122
(A and B) The expression levels of (A) b-oxidation-related genes and (B) insulin-signaling-related genes in Huh7 overexpressing control vector (WT), SIRT6,
miR-122, antagomir against miR-122 (AM122), and both SIRT6 and miR-122.
(C) b-oxidation levels, measured by OCR of Huh7 hepatocarcinoma cells overexpressing AM122, miR-122, SIRT6, siRNA against SIRT6 (siSIRT6), siSIRT6 and
AM122, or SIRT6 and miR-122. Scrambled siRNA was used as a control in the appropriate experiments. Experiments were done in biological tetra/triplicates.
(D–F) The expression levels of (D) miR-122, (E) b-oxidation-related genes, and (F) insulin-signaling-related genes in livers of WT andMOSES (TG) mice (n = 10 per
group). *p < 0.05; **p < 0.01.for ACLY and IRS2 as well (Figures 4E and 4F). Similarly, under
HFD, mice overexpressing SIRT6 showed significantly higher
expression levels of HADHB, IGFBP1, and IGFBP2 and higher
expression of CPT1, CROT, ACLY, IRS1, and IRS2 (Figures
4E and 4F). Thus, SIRT6 overexpression also increases the
levels of b-oxidation and insulin-signaling targets of miR-122
under normal chow diet and HFD.238 Cell Reports 14, 234–242, January 12, 2016 ª2016 The AuthorsLoss of SIRT6-miR-122 Correlation Is a Significant
Marker for HCC Prognosis
SIRT6 was recently shown to be a tumor suppressor that
negatively regulates aerobic glycolysis in cancer cells (Sebastia´n
et al., 2012). Reduced SIRT6 expression levels were found
in pancreatic cancer and colon adenocarcinoma. Thus, we
searched for a correlation between SIRT6 and miR-122 in HCC
A B
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Figure 5. The Correlation between Expres-
sion of SIRT6 and miR-122 Is Associated
with Decreased Survival
(A–D) Co-expression of miR-122 and SIRT6 in
tumors from a cohort of 354 liver hepatocellular
carcinoma patients. The total group of patients did
not exhibit any correlation between SIRT6 andmiR-
122 (A). The set was divided into two groups, one
consisting of 125 patients with a combined signifi-
cant and strong negative correlation between
SIRT6 and miR-122 expression levels (blue, B), and
the other composed of 229 patients in which the
expression levels SIRT6 and miR-122 do not show
a significant correlation (green, C). Kaplan-Meier
analysis of the two groups showed that the two
groups displayed significantly different survival
curves (D). Group 1 (shown in B), which is affiliated
with a strong correlation between the miR and the
gene displayed poor survival. Group 2 (shown in C),
which is associated with the lack of correlation
between the miR and the gene, exhibits improved
prognosis (p < 1.7E-5).in the complete set of 354 samples from The Cancer Genome
Atlas (TCGA). The patients’ characterizations are detailed in Ta-
ble S1. As Figure 5A shows, this complete set of patient samples
did not display any significant correlation between SIRT6 and
miR-122 expression. However, as indicated in previous studies
(Ben-Hamo and Efroni, 2013; Feldstein et al., 2012), it is possible
that only subgroups of patients actually display significant corre-
lations. Furthermore, such groups may be associated with
different disease phenotypes. Thus, it is possible that the co-
expression, measured by the correlation between SIRT6 and
miR-122, is significant in clinical subgroups associated with
effectiveness of treatment and survival of patients.We thus strat-
ified the complete set of patients into two groups (Figures 5B and
5C). One group contained the set of samples with a significant
negative correlation between SIRT6 and miR-122, and the other
group contained the remaining samples, which did not exhibit a
significant correlation between SIRT6 andmiR-122. Both groups
have the same distribution for various characterizations such as
age, gender, race, tumor grade, and stage (Figure S3). From
these analyses, we observed that the group that exhibits no cor-
relation between SIRT6 and miR-122 was affiliated with a better
prognosis (green line, Figure 5D), while the group associated
with a significant strong negative correlation (p = 4.6E-24) was
affiliated with poor prognosis (blue line, Figure 5D). Importantly,
the expression levels of neither SIRT6 alone nor miR-122
alone were significantly associated with prognosis (Figures
S4A and S4B). However, in comparison to the group with poor
prognosis, the group with better prognosis has significant higher
levels of SIRT6 or miR-122 (p = 2.68E-08 and p = 6.89E-15,Cell Reports 14, 234–242respectively; Figures S4C and S4D).
Recently, it was suggested that in order
to facilitate its long-term oncogenic poten-
tial, hepatitis C virus (HCV) sequesters
miR-122 (Luna et al., 2015). Within this
cohort, 59 patients reported with HCV,
and within those, half showed no correla-tion between SIRT6 and miR-122 and half did. Therefore, HCV
infection does not contribute to the correlation between these
genes and prognosis in HCC (Figures S4E–S4G).
Thus, the interplay between SIRT6 and miR-122 is important
for at least two physiological pathways, fatty acid b-oxidation
and liver cancer. Moreover, the correlation between their expres-
sion levels is a strong biomarker for liver cancer prognosis.
DISCUSSION
In mice, SIRT6 overexpression and deletion of miR-122 share
similar phenotypes. Thus, we examined the possibility of recip-
rocal regulation between SIRT6 and miR-122. Here, we show
that SIRT6 overexpression results in a reduction in miR-122
levels both in tissue culture and in mouse liver. This regulation
is accomplished through SIRT6 binding and deacetylation of
histone H3K56 on the MIR-122 promoter. We further showed
that miR-122 overexpression or downregulation results in a
reduction or induction of SIRT6 protein levels, respectively.
MiR-122 binds to three sites on SIRT6 30 UTR with similar
affinity, while the binding of miR-122 to full-length SIRT6 30
UTR is two orders of magnitude greater than its affinity to
each binding site alone. This regulatory pathway is also mani-
fested on the biochemical level, as miR-122 and SIRT6 regu-
late in opposite directions a similar set of metabolism-related
genes, particularly of fatty acid b-oxidation. Finally, the corre-
lation between SIRT6 and miR-122 expression levels is a
highly significant marker for human liver cancer prognosis.
Together, these findings show that SIRT6 and miR-122, January 12, 2016 ª2016 The Authors 239
reciprocally regulate each other in the liver to control various
hepatic metabolic functions.
MiR-122 is themost abundant miRNA inmammalian liver, with
fundamental physiological roles. Functional antagonism of miR-
122 results in significant de-repression of hundreds of liver
mRNAs (Burchard et al., 2010; Elme´n et al., 2008a, 2008b).
Thus, it is crucial to understand how miR-122 regulates SIRT6
within this large set of targets. Our findings demonstrate that
miR-122 can bind separately to three different loci on SIRT6
30 UTR with a KD similar to that of miR-122 binding to CAT1, a
known miR-122 target (Bhattacharyya et al., 2006). Each of the
three binding sites contains one mismatch to the miR-122
seed sequence, and BS2 and BS3 are identical; therefore, it is
not surprising that they have similar affinities to miR-122. How-
ever, in comparison to miR-122 affinity at each of the three sites
alone, the binding affinity of miR-122 to full-length SIRT6 30 UTR
was significantly greater. Thus, one can suggest a dose-depen-
dent model for miR-122 regulation of SIRT6. Under conditions
of low miR-122 expression or decreased availability due to
increased expression of other miR-122 target mRNAs, a rela-
tively small number of miR-122 molecules will occupy one or
two of the sites on SIRT6 mRNA. Conversely, under conditions
of high miR-122 expression/availability, all three loci on SIRT6
mRNA will be occupied, and the repression on SIRT6 will be
maximal. Thus, such a model suggests an indirect regulation of
SIRT6 expression by other miR-122 targets.
Mouse models of SIRT6 overexpression and miR-122 defi-
ciency exhibit many phenotypic similarities, in particular those
related to fat homeostasis (Esau et al., 2006; Kanfi et al., 2010).
This suggests that SIRT6 and miR-122 regulate each other.
Indeed, our findings strongly support such a model. Importantly,
we showed that miR-122 negatively regulates expression of the
IGF1 binding proteins, IGFBP1 and IGFBP2. Reduced IGF-1
signaling was shown to be a key marker for extended lifespan
(Holzenberger et al., 2003; Lorenzini et al., 2014). Recently, we
showed that mice overexpressing SIRT6 that display an
extended lifespan also exhibit reduced IGF-1 signaling along
with increased IGFBP1 levels. A similar effect is found in diet-
restricted mice with extended healthy lifespan. Thus, an antago-
mir against miR-122 might be a putative drug for supporting
healthy lifespan.
Overexpression of SIRT6 or its reduction by siRNA signifi-
cantly increased or decreased fatty acid b-oxidation, respec-
tively (Figure 4C). Thus, SIRT6 is an important regulator of fatty
acid b-oxidation. Moreover, knockdown of SIRT6 by siRNA
significantly reduced the effect of antagomir against miR-122
on b-oxidation (Figure 4C). This finding suggests that SIRT6
potentially mediates the negative role ofmiR-122 on hepatic fatty
acid b-oxidation. Future research is required to explore the
SIRT6-dependent pathways involved in the mechanisms that
underlie the role of SIRT6 in fatty acid b-oxidation.
SIRT6 was shown to act as a tumor suppressor that blocks
the Warburg effect in cancer cells. In line with this role of
SIRT6, Mostoslavsky and colleagues found a decrease in its
expression in pancreatic cancer and colon adenocarcinoma
(Sebastia´n et al., 2012). Min et al. suggested that SIRT6 sup-
presses the initiation of liver cancer via inhibition of surviving
(Min et al., 2012). Here, a large cohort of samples from HCC240 Cell Reports 14, 234–242, January 12, 2016 ª2016 The Authorspatients did not exhibit a negative correlation between SIRT6
and miR-122 levels. However, when we stratified the patients
using the presence of this correlation as a marker, we saw
that lower survival was significantly associated with a negative
correlation between miR-122 and SIRT6, while individuals with
a high survival rate did not display this miR-gene correlation
(Figure 5). Both SIRT6 and miR-122 were reported to act as
tumor suppressors. Thus, perhaps in order to enable better
survival rates of individuals, and in line with our findings, we
find a loss of this reciprocal negative regulation and significantly
higher expression of miR-122 and SIRT6 in patients with better
prognosis (Figure 5; Figure S4). This further supports the possi-
bility of using SIRT6-miR-122 correlation as a prognostic
marker. Moreover, this study suggests a future research aim
of developing agents that will disrupt the reciprocal regulation
as a therapeutic approach for HCC.
The anticancer role of tumor suppressors is only secondary to
its primary cellular function. During evolution, these proteins
each evolved to their main cellular functions, which was later
used in the context of cancer. For example, p53’s primary phys-
iological function is to act as a guardian of the genome and an
executer of the apoptosis cascade, such as during development,
yet this function also serves in the pathological condition of
cancer. Similarly, miR-122 and SIRT6 may have developed
during evolution as regulators of liver function, primarily hepatic
lipid metabolism. Likewise, one of SIRT6’s primary functions is a
regulator of glycolysis; this function also serves in the patholog-
ical condition of cancer. Thus, the primary functions of miR-122
and SIRT6 also play a major role in their tumor suppressor
functions. This allows each independently to be developed as
a tumor suppressor. Indeed, overexpression of miR-122 or
SIRT6 in Huh7 HCC cells reduces the expression levels of four
HCC-related genes, AFP, H19, GPC3, and IGF2 (Figure S5A)
(Marquardt et al., 2013). However, in healthy livers, in compari-
son to WT, the expression of these genes was only slightly lower
in MOSES mice (Figure S5B). These findings suggest that the
repressive effect of SIRT6 and potentially miR-122 on these
genes is enhanced under pathological cancer conditions. We
predict that under conditions by which one of these is mutated,
as was found in many tumors for SIRT6 (Sebastia´n et al., 2012),
the other will function as a tumor suppressor. However, as we
demonstrated, due to their opposite regulation, in other cases
loss of this reciprocal negative regulation will enhance their anti-
tumor potential.
Altogether, these findings explore a regulatory interaction
between SIRT6 and miR-122 in liver metabolism and in HCC,
and they suggest the use of miR-122 modulator in the therapy
of SIRT6-regulated metabolic diseases and cancer.EXPERIMENTAL PROCEDURES
Animals
Mice were kept as previously described (Kanfi et al., 2010). All experiments
were conducted in accordance with the Institutional Animal Care and Use
Committee. The Sirt6-tg/MOSES transgenic strain on CB6 background and
the conditions of the high-fat diet experiment were described previously (Kanfi
et al., 2010). For mouse experiments, 6-month-old male mice (WT and SIRT6
transgenic) were sacrificed, and RNA was purified from livers and processed
as described in the section Gene Expression Analysis below.
Cell Culture and Reagents
The Huh7 human hepatocarcinoma cell line was grown in complete DMEM (low
glucose) supplemented with 10% fetal calf serum, 1% penicillin-streptomycin
mixture, and L-glutamine. Transfection was performed using the lipofectamine
(Invitrogen) method. The cells were harvested 48 hr after transfection. For
SIRT6 transfections, 2 mg DNA (6-well plate) or 10 mg DNA (10-cm plate) was
used. For siRNA transfections, cellswere transfectedwith siRNAs (IDT) at a con-
centration of 50 nM, using DharmaFECT1 (Dharmacon), and harvested as indi-
cated. MiR-122 and anti-miR-122 were purchased from Applied Biosystems
by Life Technologies and transfected using siPORTNeoFX transfection reagent.
Lysate Preparation and Immunoblotting
Protein extraction and western blot analysis were performed as previously
described (Elhanati et al., 2013). Table S3 describes the antibodies used for
the immunoblot analysis.
Gene Expression Analysis
RNA extraction and quantitative real-time PCR were performed as previously
described (Elhanati et al., 2013). MicroRNA levels were determined using
TaqMan MicroRNA Assay (Applied Biosystems). A list of PCR primers is avail-
able upon request.
Luciferase Assay
Dual-Luciferase Reporter Assay System (DLR Assay System; Promega) was
used to measure luciferase activity of cells transfected with psiCHECKTM-2
vector encoding SIRT6 30 UTR downstream to the Renilla Luciferase gene.
DLR assay was conducted 48 hr posttransfection according to the manufac-
turer’s instructions. Luciferase assays were analyzed on the basis of ratio of
Renilla/Firefly (psiCHECK2-based vectors) to normalize cell number and trans-
fection efficiency. In the experiment with mutated miR-122, each well differed
in the miR-122 expression plasmid, with miR-Vec vector that expresses no
mir (Vehicle), miR-122 (WT), or miR-122 harboring two (double mutants) or
three mutations (triple mutants) in its seed region. To generate the mutation,
the WT sequence UGGAGUGUGACAAUGGUGUUUG was mutated into
UGUAUUGUGACAAUGGUGUUUG (double-mutant miR-122) or UUUAUUGU
GACAAUGGUGUUUG (triple-mutant miR-122). The seed sequence of the WT
and the mutated seed sequences are underlined. To mutate BS1, BS2, and
BS3, the sites were changed into CTCCAGGCCAGGGGTTACACCTGCCC
AAATT GGTC, GGTTCCGGGAAGAAGCCACCGCGGAGAGGT, and TGAC
AGCTGAGC CCCTGCCCCAGCGGAGCCTCTG, respectively (the mutated
nucleotides are underlined).
Chromatin Immunoprecipitation
Experimentswere performed as previously described (Kanfi et al., 2010). Briefly,
formaldehyde fixation (final concentration of 1%) was done at 37C for 10 min,
and cells were then harvested by scraping in ice-cold PBS containing protease
inhibitor. Resuspended cell pellets in lysis buffer was then sonicated to shear
DNA to segments of 500–1,000 bp. Sonication was done using three pulses of
30 s, with 2 min on ice in between pulses and at 40% strength. After centrifuga-
tion, the chromatin solution was precleared with the addition of protein A/G
agarose beads for 45 min at 4C. Thereafter, each sample was incubated with
2 mg of the indicated antibody overnight at 4C (an anti-H3 antibody was used
as a positive control, and an anti-IgG antibody was used as a negative control),
washed with several wash buffers to reduce background, and then eluted with
NaHCO3 (50 mM). Crosslinking was reversed by addition of NaCl to a final con-
centration of 200mM.Next, 20 ml proteinase K solution, 50mMTris (pH 7.5), and
10mMEDTAwere added to a total elution volume of 500ml. DNA samples were
purifiedby aPCRcleanupkit (Promega). Eachgenewas analyzedup to2,000bp
upstream of its transcription start site, in segments of 700 bp, each tested sepa-
rately with a distinct set of primers by quantitative real-time PCR. To calculate
‘‘DNA fold enrichment,’’ the following formula was used: 2^-(Ct IP-Ct input) 
(Ct IP  Ct IgG), where IgG serves as negative control. Table S2 shows the
sequences of the primers that were used for the ChIP analysis.
Fatty Acid Oxidation and Cellular Oxygen Consumption
Mitochondrial fatty acid oxidation (FAO) rate and cellular oxygen consumption
were measured using the Seahorse XF24 analyzer according to the manufac-Cturer’s protocol. The increased OCR following BSA-conjugated palmitate
addition was measured using the XF24 extracellular flux analyzer (Seahorse
Bioscience), according to manufacturer’s instructions.
Surface Plasmon Resonance
SPR assays were performed using Biacore T100 biosensor (GE Healthcare).
Streptavidin (200 ug/mL in 10 mM sodium acetate [pH 5]) was coupled to all
four positions of CM5 Biosensor Chips (GE Healthcare) using standard amine
coupling protocol. The first channel position was used as a reference. Bio-
tinylated RNA oligomer stock solutions (1 mM) were dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (Sigma-Aldrich) and were diluted 1:5,000 in the running
buffer for immobilization.BiotinylatedRNAattachmentwasperformedsequen-
tially in the appropriate flow channels using HBS-EP buffer (10 mM HEPES
[pH 7.3], 150mMNaCl, 3mMEDTA, and 0.005%Tween20). Analyte RNA, con-
sisting of 30 UTR, fragments thereof,which compriseputativemiRbinding sites,
and control fragments were prepared as concentration series (0.078 mg/mL to
2.5 mg/mL) and then were injected in order of increasing concentration, with
10 mM NaOH, 1 M NaCl regeneration solution applied for 30 s between each
cycle. The binding parameters were evaluated using the Kinetic 1:1 Binding
model in BiaEvaluation software v. 3.0.1 (GE Healthcare).
Computational Analysis
Data for this analysis were downloaded from TCGA dataset (http://
cancergenome.nih.gov/). The data are composed of Illumina RNA sequencing
(RNA-seq) files, microRNA-Seq and clinical information from 354 liver HCC
patients. All patients were included in the analysis without exclusion. A feature
selection algorithm was applied to the SIRT6 and hsa-miR-122 expression
levels to identify a subgroup with a significant strong correlation, and its
complement group, with insignificant correlation as detailed in (Ben-Hamo
and Efroni, 2013). Kaplan-Meier analysis was performed to determine groups’
clinical affiliation.
Statistical Analyses
Significant differences between two groups were assessed by two-tailed
Mann-Whitney test. Data are expressed as means ± SEM. Values of p <
0.05 were considered to be statistically significant. All experiments were per-
formed at least three times.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and three tables and can be
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